OTC · Financial Statements
Arch Therapeutics, Inc. (ARTH) Financial Statements
$0.00
OTC: ARTH
Market Cap $444
Overview Financials Dividend
Arch Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $7.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023
Revenue $0 $0 $0 $0 $0 Operating Profit $-6.0M $-5.0M $-6.0M $-6.0M $-5.0M Net Profit $-3.0M $-4.0M $-7.0M $-4.0M $-7.0M EPS $-3.27 $-4.27 $-5.97 $-3.56 $-2.27 Op Margin — — -55141.6% -36473.3% -6661.7%
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023
Total Assets $3.0M $2.0M $4.0M $3.0M $2.0M Total Liabilities $4.0M $4.0M $5.0M $7.0M $9.0M Cash $2.0M $1.0M $2.0M $1.0M $0 Borrowings $0 $1.0M $2.0M $3.0M $6.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023
Operating Cash Flow $-5.0M $-5.0M $-6.0M $-4.0M $-3.0M Investing Cash Flow $0 $0 $0 $0 $0 Financing Cash Flow $0 $1.0M $0 $0 $0 Net Cash Flow $-2.0M $-1.0M $1.0M $-2.0M $-1.0M Free Cash Flow $-5.0M $-5.0M $-6.0M $-4.0M $-3.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA -1.39 FCF Yield -760976.80% Quick Ratio 0.06 Interest Coverage -1.63 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .